Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Rare Disease Policy topic
No spam. Unsubscribe anytime.
Committee lays over funding bill for Rare Disease Advisory Council amid federal program uncertainty
Summary
Senate File 2037 to fund the Minnesota Rare Disease Advisory Council was laid over after the council's executive director told the committee that recent federal restructuring and grant pauses increased the urgency of state-level support for newborn screening and gene-therapy readiness.
The committee heard Senate File 2037, which would provide resources to the Minnesota Rare Disease Advisory Council (RDAC). Erica Barnes, executive director of RDAC, described work the council has done with prior funding: connecting patient groups to researchers, developing a presumptive-eligibility policy to speed care, launching a gene-therapy reimbursement task force, and initiating tele-mentoring to spread specialist knowledge.
Barnes said recent federal restructuring and paused grant activities increased urgency for state-level work. "The advisory committee on heritable disorders in newborns and children... has been paused," she said, and noted that a federal review meeting about adding a treatable rare disease to the recommended newborn screening panel had been canceled. Barnes urged the Legislature to maintain funding so Minnesota can continue newborn screening advancement, gene-therapy readiness and support services for affected families.
Committee members expressed support and concern about federal actions. Senators noted Minnesota's leadership role and the potential ripple effects of federal pauses on newborn screening and clinical research. The committee laid Senate File 2037 over for possible inclusion.
